Abgn-168h - a humanized, agonistic monoclonal antibody against p selectin glycoprotein ligand-1 (psgl-1; selplg; cd162), with potential immunosuppressive activity. Upon administration, neihulizumab specifically targets and binds to cd162 expressed on activated t-lymphocytes. This induces apoptosis of activated t-cells and reduces t-cell-mediated immune responses. This may halt disease progression of t-cell-mediated autoimmune diseases and acute graft-versus-host disease (gvhd). Also see neihulizumab
Up to date info
Latest research - Abgn-168h
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Abgn-168h for any updates.